-
CMT introudctions
China Medical Tribune was founded in 1983. It is a professional medical media co-founded by the former Ministry of Health and Sackler Foundation. It is a public institution under the Center for International Exchange and Cooperation, National Health Commission. CMT adheres to the spirit of dedication, innovation and responsibility. It is committed to conveying the advances and attracting fields of studies in medical science and clinical practice at home and abroad to 2 million Chinese doctors in the principle of evidence-based reporting methods; and it also provides the latest medical information and solutions to clinical problems. CMT listens to different academic voices and delivers objective medical information to Chinese clinical workers. It is currently one of the largest and most influential professional medical newspaper in China. In addition to the newspaper business, it also covers the scope of online media platforms, including its one and only official medical education-based application CMTopDr, the matrix of wechat public accounts and customized platforms for live conference broadcasting, surveys and collection of real-world medical records.
2020-04-23 16227 看过 免费 -
悉听我说第一期
2020-04-22 29436 看过 免费 -
疫情之下的医院管理
2020-04-21 31121 看过 免费 -
“炎症风暴”多学科对话（下）
“炎症风暴”多学科对话（下）协办媒体：中国医学论坛报社
2020-04-18 91412 看过 免费 -
药事管理知识面面谈
药事管理知识面面谈
2020-04-15 31560 看过 免费 -
空中对话|疫路求索再线关爱第二期
协办单位：中国医学论坛报社
2020-04-15 27264 看过 免费 -
第五期 守正创新，坚持中西医并重下
中西医荟萃 守正创新，坚持中西医并重 下
2020-04-13 97162 看过 免费 -
“炎症风暴”多学科对话（上）
协办媒体：中国医学论坛报社
2020-04-11 95765 看过 免费 -
第四期 守正创新，坚持中西医并重上
中西医荟萃 守正创新，坚持中西医并重 上
2020-04-09 102950 看过 免费 -
空中对话|疫路求索再线关爱第一期
协办单位：中国医学论坛报社
2020-04-08 28239 看过 免费
直播预告
热门资讯
- 专访母义明教授④：体重管理面临的主要挑战与应对措施
- 专访母义明教授②：GLP-1RA类代表药物利拉鲁肽、司美格鲁肽、替尔泊肽的特点与临床应用
- 专访母义明教授③：未来GLP-1类药物研究的关键方向
- 专访母义明教授①：GLP-1RA发展历程中的重要突破
- 李丹教授：从临床实践及循证医学证据看——重症ILD如何使用糖皮质激素和抗纤维化药物
- 减重新药解读！新一代偏向型GLP-1到底偏向哪里？机制与疗效有何不同？
- 李丹教授：糖皮质激素和抗纤维化药物治疗重症间质性肺炎的作用机制
- 罗红教授：下呼吸道病原学的精准治疗——mNGS与tNGS该如何选择应用时机？
- 中国Ⅲ期数据重磅发布，埃诺格鲁肽带来93%有效减重，多维代谢获益亮眼
- 李国强教授：血液灌流治疗脓毒症的应用探讨——目标人群
